Impact of anemia on organ functions

  • M. R. Nowrousian


The immediate effect of anemia is a decreased oxygen-carrying capacity of the blood and, consequently, a decreased supply of oxygen to various organs. The resultant tissue hypoxia evokes a number of compensatory mechanisms and a series of physiological and metabolic abnormalities that are responsible for the clinical signs and symptoms of anemia and cause limitations in physical and mental well-being of patients and their quality of life (QoL). Recent clinical studies show that anemia has much greater impacts on tissue and organ functions than previously thought, and that chronic anemia may be a risk factor not only for morbidity, but also for mortality. In this overview, the results of these studies, and particularly the relationship between the physiological and metabolic changes induced by anemia and their impacts on organ functions, physical and mental well-being and QoL will be discussed.


Iron Overload Recombinant Human Erythropoietin Nephrol Dial Transplant Chronic Anemia Serum Ferritin Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abayomi OK (1996) Pathogenesis of irradiation-induced cognitive dysfunction. Acta Oncol 35: 659–663PubMedCrossRefGoogle Scholar
  2. 2.
    Abels RI (1992) Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 19 (Suppl 8): 29–35PubMedGoogle Scholar
  3. 3.
    Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC (1993) Pathogenesis of oedema in chronic severe anemia: studies of body water and sodium, renal function, hemodynamic variables, and plasma hormones. Br Heart J 70: 357–362PubMedCrossRefGoogle Scholar
  4. 4.
    Barany P, Pettersson E, Ahlberg M, Hultman E, Bergstrom J (1991) Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin. Clin Nephrol 35: 270–279PubMedGoogle Scholar
  5. 5.
    Barrett-Lee PJ, Baily NP, O’Brien ME, Wager E (2000) Large-scale UK audit of blood transfusion requirements and anemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82: 93–97PubMedCrossRefGoogle Scholar
  6. 6.
    Barton JC, Bertoli LF (2000) Transfusion iron overload in adults with acute leukemia: manifestations and therapy. Am J Med Sci 319: 73–78PubMedCrossRefGoogle Scholar
  7. 7.
    Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584–590PubMedCrossRefGoogle Scholar
  8. 8.
    Birmingham DJ, Shen XP, Hartman JA, Dillon JJ, Hebert LA (1996) Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. Kidney Int 50: 543–549PubMedCrossRefGoogle Scholar
  9. 9.
    Boelaert JR, Cantinieaux BF, Hariga CF, Fondu PG (1990a) Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 5: 504–517PubMedGoogle Scholar
  10. 10.
    Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW (1990b) Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 5: 130–134PubMedGoogle Scholar
  11. 11.
    Bottomley SS (1998) Secondary iron overload disorders. Semin Hematol 35: 77–86PubMedGoogle Scholar
  12. 12.
    Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18: 2695–2701PubMedGoogle Scholar
  13. 13.
    Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97: 10526–10531Google Scholar
  14. 14.
    Bryl E, Mysliwska J, Debska-Slizien A, Rachon D, Bullo B, Lizakowski S, Mysliwski A, Rutkowski B (1998) The influence of recombinant human erythropoietin on tumor necrosis factor alpha and interleukin-10 production by whole blood cell cultures in hemodialysis patients. Artif Organs 22: 177–181PubMedCrossRefGoogle Scholar
  15. 15.
    Bryl E, Mysliwska J, Debska-Slizien A, Trzonkowski P, Rachon D, Bullo B, Zdrojewski Z, Mysliwski A, Rutkowski B (1999) Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of hemodialysis patients. Artif Organs 23: 809–816PubMedCrossRefGoogle Scholar
  16. 16.
    Canadian Erythropoietin Study Group (1990) Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300: 573–578Google Scholar
  17. 17.
    Cantinieaux B, Boelaert J, Hariga C, Fondu P (1988) Impaired neutrophil defense against Yersinia enterocolitica in patients with iron overload who are undergoing dialysis. J Lab Clin Med 111: 524–528PubMedGoogle Scholar
  18. 18.
    Cella D, Bron D (1999) The effect of Epoetin alfa on quality of life in anemic cancer patients. Cancer Pract 7: 177–182PubMedCrossRefGoogle Scholar
  19. 19.
    Cerami A, Brines ML, Ghezzi P, Cerami CJ (2001) Effects of epoetin alfa on the central nervous system. Semin Oncol 28 (Suppl 8): 66–70PubMedCrossRefGoogle Scholar
  20. 20.
    Chan MK (1990) Lipid metabolism in renal failure. Clin Biochem 23: 61–65PubMedCrossRefGoogle Scholar
  21. 21.
    Chan MK, Varghese Z, Moorhead JF (1981) Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int 19: 625–637PubMedCrossRefGoogle Scholar
  22. 22.
    Chin K, Yu X, Beleslin-Cokic B, Liu C, Shen K, Mohrenweiser HW, Noguchi CT (2000) Production and processing of erythropoietin receptor transcripts in brain. Brain Res Mol Brain Res 81: 29–42PubMedCrossRefGoogle Scholar
  23. 23.
    Clyne N, Jogestrand T (1992) Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 60: 390–396PubMedCrossRefGoogle Scholar
  24. 24.
    Collins AJ, Ma JZ, Ebben J (2000) Impact of hematocrit on morbidity and mortality. Semin Nephrol 20: 345–349PubMedGoogle Scholar
  25. 25.
    Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292–295PubMedCrossRefGoogle Scholar
  26. 26.
    Dame C, Juul SE, Christensen RD (2001) The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate 79: 228–235PubMedCrossRefGoogle Scholar
  27. 27.
    Daneryd P, Svanberg E, Körner U, Lindholm E, Sandström R, Brevinge H, Pettersson C, Bosaeus I, Lundholm K (1998) Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res 58: 5374–5379PubMedGoogle Scholar
  28. 28.
    Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412–3425PubMedGoogle Scholar
  29. 29.
    Diesel W, Noakes TD, Swanepoel C, Lambert M (1990) Isokinetic muscle strength predicts maximum exercise tolerance in renal patients on chronic hemodialysis. Am J Kidney Dis 16: 109–114PubMedGoogle Scholar
  30. 30.
    Drueke TB, Eckardt KU, Frei U, Jacobs C, Kokot F, McMahon LP, Schaefer RM (1999) Does early anemia correction prevent complications of chronic renal failure? Clin Nephrol 51: 1–11PubMedGoogle Scholar
  31. 31.
    Eckardt KU (2000) Pathophysiology of renal anemia. Clin Nephrol 53 (Suppl 1): S2 - S8PubMedGoogle Scholar
  32. 32.
    Emy PY, Levin TL, Sheth SS, Ruzal-Shapiro C, Garvin J, Berdon WE (1997) Iron overload in reticuloendothelial systems of pediatric oncology patients who have undergone transfusions: MR observations. AJR Am J Roentgenol 168: 1011–1015PubMedGoogle Scholar
  33. 33.
    Eschbach JW, Adamson JW (1999) Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int Suppl 69: S35 - S43PubMedCrossRefGoogle Scholar
  34. 34.
    Evans RW (1991) Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: a comparative analysis. Am J Kidney Dis 18: 62–70PubMedGoogle Scholar
  35. 35.
    Fagher B, Thysell H, Monti M (1994) Effect of erythropoietin on muscle metabolic rate, as measured by direct microcalorimetry, and ATP in hemodialysis patients. Nephron 67: 167–171PubMedCrossRefGoogle Scholar
  36. 36.
    Fatouros MS, Vekinis G, Bourantas KL, Mylonakis EP, Scopelitou AS, Malamou-Mitis VD, Kappas AM (1999) Influence of growth factors erythropoietin and granulocyte macrophage colony-stimulating factor on mechanical strength and healing of colonic anastomosis in rats. Eur J Surg 165: 986–992PubMedCrossRefGoogle Scholar
  37. 37.
    Flament J, Goldman M, Waterlot Y, Dupont E, Wybran J, Vanherweghem JL (1986) Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clin Nephrol 25: 227–230PubMedGoogle Scholar
  38. 38.
    Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE (1996) The impact of anemia on cardiomyopathy, morbidity, and and mortality ih end-stage renal disease. Am J Kidney Dis 28: 53–61PubMedCrossRefGoogle Scholar
  39. 39.
    Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE (2000a) Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11: 912–916PubMedGoogle Scholar
  40. 40.
    Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells G (2000b) Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58: 1325–1335PubMedCrossRefGoogle Scholar
  41. 41.
    Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875–2882PubMedGoogle Scholar
  42. 42.
    Glaser C, Millesi W (1998) r-HuErythropoietin supply increases efficacy of neo-adjuvant radiochemotherapy in patients with oral squamous cell carcinoma. Proc Am Soc Clin Oncol 17: 397a (Abstr 1532 )Google Scholar
  43. 43.
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218–1234PubMedGoogle Scholar
  44. 44.
    Glans A, Müller S (2000) [Hemoglobin and fatigue in cancer patients: inseparable twins?]. Schweiz Med Wochenschr 130: 471–477Google Scholar
  45. 45.
    Goto T, Saika H, Takahashi T, Maeda A, Mune M, Yukawa S (1999) Erythropoietin supplement increases plasma lipoprotein lipase and hepatic triglyceride lipase levels in hemodialysis patients. Kidney Int (Suppl) 71: 5213 - S215Google Scholar
  46. 46.
    Grimm G, Stockenhuber F, Schneeweiss B, Madl C, Zeitlhofer J, Schneider B (1990) Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 38: 480–486PubMedCrossRefGoogle Scholar
  47. 47.
    Grimm PC, Sinai-Trieman L, Sekiya NM, Robertson LS, Robinson BJ, Fine RN, Ettenger RB (1990) Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 38: 12–18PubMedCrossRefGoogle Scholar
  48. 48.
    Grossman W, Jones D, McLaurin LP (1975) Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56: 56–64PubMedCrossRefGoogle Scholar
  49. 49.
    Harrison P, Neilson JR, Marwah SS, Madden L, Bareford D, Milligan DW (1996) Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation. J Clin Pathol 49: 853–856PubMedCrossRefGoogle Scholar
  50. 50.
    Hebert LA, Birmingham DJ, Dillon JJ, Cosio FG, Shen XP (1994) Erythropoietin therapy in humans increases erythrocyte expression of complement receptor type 1 (CD35). J Am Soc Nephrol 4: 1786–1791PubMedGoogle Scholar
  51. 51.
    Hellström-Lindberg E, Ahigren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Lofvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Oberg G, Österborg A, Ost A (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92: 68–75PubMedGoogle Scholar
  52. 52.
    Hershko C, Peto TE, Weatherall DJ (1988) Iron and infection. Br Med J (Clin Res Ed) 296: 660–664CrossRefGoogle Scholar
  53. 53.
    Hoen B, Kessler M, Hestin D, Mayeux D (1995) Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 10: 377–381PubMedGoogle Scholar
  54. 54.
    Ikizler TA, Hakim RM (1996) Nutrition in end-stage renal disease. Kidney Int 50: 343–357PubMedCrossRefGoogle Scholar
  55. 55.
    Kaltwasser JP, Gottschalk R (1999) Erythropoietin and iron. Kidney Int (Suppl) 69: S49 - S56CrossRefGoogle Scholar
  56. 56.
    Kausz AT, Obrador GT, Pereira BJ (2000) Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 36: S39 - S51PubMedCrossRefGoogle Scholar
  57. 57.
    Kelekis NL, Semelka RC, Jeon HJ, Sallah AS, Shea TC, Woosley JT (1996) Dark ring sign: finding in patients with fungal liver lesions and transfusional hemosiderosis undergoing treatment with antifungal antibiotics. Magn Reson Imaging 14: 615–618PubMedCrossRefGoogle Scholar
  58. 58.
    Kettner-Melsheimer A, Weiss M, Huber W (1987) Physical work capacity in chronic renal disease. Int J Artif Organs 10: 23–30PubMedGoogle Scholar
  59. 59.
    Kimata H, Yoshida A, Ishioka C, Masuda S, Sasaki R, Mikawa H (1991) Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium. Clin Exp Immunol 85: 151–156PubMedCrossRefGoogle Scholar
  60. 60.
    Kokot F, Wiecek A, Mesjasz J, Adamczak M, Spiechowicz U (1998) Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients. Nephrol Dial Transplant 13: 1200–1205PubMedCrossRefGoogle Scholar
  61. 61.
    Lawrence IG, Price DE, Howlett TA, Harris KP, Feehally J, Walls J (1997) Erythropoietin and sexual dysfunction. Nephrol Dial Transplant 12: 741–747PubMedCrossRefGoogle Scholar
  62. 62.
    Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H (1994) Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73: 2535–2542PubMedCrossRefGoogle Scholar
  63. 63.
    Levin A, Foley RN (2000) Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 36: S24 - S30PubMedCrossRefGoogle Scholar
  64. 64.
    Levin NW (1992) Quality of life and hematocrit level. Am J Kidney Dis 20: 16–20PubMedGoogle Scholar
  65. 65.
    Lichtman SM, Attivissimo L, Goldman IS, Schuster MW, Buchbinder A (1999) Secondary hemochromatosis as a long-term complication of the treatment of hematologic malignancies. Am J Hematol 61: 262–264PubMedCrossRefGoogle Scholar
  66. 66.
    Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B for the Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874PubMedGoogle Scholar
  67. 67.
    Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322: 1693–1699PubMedCrossRefGoogle Scholar
  68. 68.
    Lumadue JA, Ness PM (1996) Current approaches to red blood cell transfusion. Semin Hematol 33: 277–289PubMedGoogle Scholar
  69. 69.
    Macdougall IC (1998) Quality of life and anemia: the nephrology experience. Semin Oncol 25 (Suppl 7): 39–42PubMedGoogle Scholar
  70. 70.
    Macdougall IC (2001) Should the hematocrit be normalized in dialysis and in pre-ESRD patients? Blood Purif 19: 157–167PubMedCrossRefGoogle Scholar
  71. 71.
    Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KA, Coles GA, Williams JD (1990) Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335: 489–493PubMedCrossRefGoogle Scholar
  72. 72.
    Mak RH (1996a) Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia. Am J Physiol 270: F839 - F844PubMedGoogle Scholar
  73. 73.
    Mak RH (1996b) Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. J Pediatr 129: 97–104PubMedCrossRefGoogle Scholar
  74. 74.
    Mak RH (1998) Metabolic effects of erythropoietin in patients on peritoneal dialysis. Pediatr Nephrol 12: 660–665PubMedCrossRefGoogle Scholar
  75. 75.
    Mann JF (1999) What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant 14: 29–36PubMedCrossRefGoogle Scholar
  76. 76.
    Marsh JT, Brown WS, Wolcott D, Carr CR, Harper R, Schweitzer SV, Nissenson AR (1991) rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 39: 155–163Google Scholar
  77. 77.
    McKay PJ, Murphy JA, Cameron S, Burnett AK, Campbell M, Tansey P, Franklin IM (1996) Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 17: 63–66PubMedGoogle Scholar
  78. 78.
    McMahon LP, McKenna MJ, Sangkaburta T, Mason K, Sostaric S, Skinner S, Burge C, Murphy B, Crankshaw D (1999) Physical performance and associated electrolyte changes after hemoglobin normalization: a comparative study in hemodialysis patients. Nephrol Dial Transplant 14: 1182–1187PubMedCrossRefGoogle Scholar
  79. 79.
    Merkel PA, Simonson DC, Amiel SA, Plewe G, Sherwin RS, Pearson HA, Tamborlane WV (1988) Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 318: 809–814PubMedCrossRefGoogle Scholar
  80. 80.
    Metry G, Wikstrom B, Valind S, Sandhagen B, Linde T, Beshara S, Langstrom B, Danielson BG (1999) Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. J Am Soc Nephrol 10: 854–863PubMedGoogle Scholar
  81. 81.
    Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N (2001) Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 98: 5181–5186PubMedCrossRefGoogle Scholar
  82. 82.
    Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F (2000) Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 11: 335–342PubMedGoogle Scholar
  83. 83.
    Murphy MF, Wallington TB, Kelsey P, Boulton F, Bruce M, Cohen H, Duguid J, Knowles SM, Poole G, Williamson LM (2001) Guidelines for the clinical use of red cell transfusions. Br J Haematol 113: 24–31PubMedCrossRefGoogle Scholar
  84. 84.
    Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87: 4076–4081PubMedGoogle Scholar
  85. 85.
    Nishizawa Y, Shoji T, Tanaka S, Yamashita M, Morita A, Emoto M, Tabata T, Inoue T, Morii H (1998) Plasma leptin level and its relationship with body composition in hemodialysis patients. Am J Kidney Dis 31: 655–661PubMedCrossRefGoogle Scholar
  86. 86.
    Nissenson AR (1989) Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol 9: 25–31PubMedGoogle Scholar
  87. 87.
    Nowrousian MR, Kasper C, Oberhoff C, Essers U, Voigtmann R, Gallasch W, Quarder O (1996) Pathophysiology of cancer-related anemia. In: Smyth JF, Boogaerts MA, Ehmer BRM (eds) rhErythropoietin in cancer supportive treatment. Marcel Dekker, New York, pp 13–34Google Scholar
  88. 88.
    Nowrousian MR (1998) Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 15 (Suppl 1): S19 - S28PubMedGoogle Scholar
  89. 89.
    Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrmann R, Netter-Pinon J, Tubiana-Mathieu N, Zwierzina H (1998) Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 9: 255–260PubMedCrossRefGoogle Scholar
  90. 90.
    Paczek L, Schaefer RM, Heidland A (1990) Improved function of B lymphocytes in dialysis patients treated by recombinant human erythropoietin. Contrib Nephrol 87: 36–41PubMedGoogle Scholar
  91. 91.
    Palmer BF (1999) Sexual dysfunction in uremia. J Am Soc Nephrol 10: 1381–1388PubMedGoogle Scholar
  92. 92.
    Patruta SI, Horl WH (1999) Iron and infection. Kidney Int Suppl 69: 5125–5130Google Scholar
  93. 93.
    Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH (1998) Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9: 655–663PubMedGoogle Scholar
  94. 94.
    Pfaffl W, Gross HJ, Neumeier D, Nattermann U, Samtleben W, Gurland HJ (1988) Lymphocyte subsets and delayed cutaneous hypersensitivity in hemodialysis patients receiving recombinant human erythropoietin. Contrib Nephrol 66: 195–204PubMedGoogle Scholar
  95. 95.
    Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR (1999) Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 33: 1122–1130PubMedCrossRefGoogle Scholar
  96. 96.
    Pierelli L, Perillo A, Greggi S, Salerno G, Panici PB, Menichella G, Fattorossi A, Leone G, Mancuso S, Scambia G (1999) Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol 17: 1288–1295PubMedGoogle Scholar
  97. 97.
    Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL (1995) Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25: 548–554PubMedCrossRefGoogle Scholar
  98. 98.
    Riedel E, Nundel M, Wendel G, Hampl H (2000) Clin Nephrol 53 (Suppl 1): S56 — S60PubMedGoogle Scholar
  99. 99.
    Rosner F, Grünewald HW (1997) The patient with anemia. Med Update for Psychiatrists 2: 177–180CrossRefGoogle Scholar
  100. 100.
    Rossi EC (1994) Red cell transfusion therapy in chronic anemia. Hematol Oncol Clin North Am 8: 1045–1052PubMedGoogle Scholar
  101. 101.
    Russo F, Guadagni S, Mattera G, Esposito G, Abate G (1999) Combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin ( EPO) for the treatment of advanced non-responsive chronic lymphocytic leukemia. Eur J Haematol 63: 325–331Google Scholar
  102. 102.
    Sagaies T, Gimeno V, Planella MJ, Raguer N, Bartolome J (1993) Effects of rHuEPO on Q-EEG and event-related potentials in chronic renal failure. Kidney Int 44: 1109–1115CrossRefGoogle Scholar
  103. 103.
    Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95: 4635–4640PubMedCrossRefGoogle Scholar
  104. 104.
    Sarnak MJ, Levey AS (2000) Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 35: S117 - S131PubMedCrossRefGoogle Scholar
  105. 105.
    Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, Bunn HF (1981) Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 304: 319–324PubMedCrossRefGoogle Scholar
  106. 106.
    Schleiffenbaum B (1994). Verminderte Sauerstofftransport-Kapazität als Ursache von Dyspnoe. Schweiz Med Wochenschr 124: 1177–1182PubMedGoogle Scholar
  107. 107.
    Seifert A, von Herrath D, Schaefer K (1987) Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 65: 1015–1024PubMedGoogle Scholar
  108. 108.
    Sennesael JJ, Van der Niepen P, Verbeelen DL (1991) Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 40: 121–128PubMedCrossRefGoogle Scholar
  109. 109.
    Shurtz-Swirski R, Kristal B, Shkolnik T, Weissman I, Shapiro G, Shasha SM (1996) Short-term effect of erythropoietin on T-cell mitogenic proliferation in chronic renal failure patients. Nephron 72: 27–29PubMedCrossRefGoogle Scholar
  110. 110.
    Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Brauch R, Koifman B, Kaplan C, Steinbruch S, Iaina A (2000) The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalisation. J Am Coll Cardiol 35: 1737–1744PubMedCrossRefGoogle Scholar
  111. 111.
    Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A (2001a) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomised controlled study. J Am Coll Cardiol 37: 1775–1780PubMedCrossRefGoogle Scholar
  112. 112.
    Silverberg DS, Iaina A, Wexler D, Blum M (2001b) The pathological consequences of anemia. Clin Lab Haematol 23: 1–6PubMedCrossRefGoogle Scholar
  113. 113.
    Singh AB, Singh M, Palekar S, Levy S, Nunn C, Mann RA (1992) The effects of recombinant human erythropoietin on the cell mediated immune response of renal failure patients. J Med 23: 289–302PubMedGoogle Scholar
  114. 114.
    Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 98: 4044–4049PubMedCrossRefGoogle Scholar
  115. 115.
    Sommerburg O, Grune T, Hampl H, Riedel E, Ehrich JH, Siems WG (2000) Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients? Clin Nephrol 53 (Suppl 1): S23 - S29PubMedGoogle Scholar
  116. 116.
    Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK, Barendt J, Platzer E, Moore MAS, Mertelsmann R, Welte K (1986) Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232: 61–65PubMedCrossRefGoogle Scholar
  117. 117.
    Sowade O, Gross J, Sowade B, Warnke H, Franke W, Messinger D, Scigalla P, Lun A, Glatzel E (1997) Evaluation of oxygen availability with oxygen status algorithm in patients undergoing open heart surgery treated with epoetin beta. J Lab Clin Med 129: 97–105PubMedCrossRefGoogle Scholar
  118. 118.
    Spaia S, Pangalos M, Askepidis N, Pazarlogolou M, Mavropoulou E, Theodoridis S, Dimitrakopolous K, Milionis A, Vayonas G (2000) Nephron 84: 320–325PubMedCrossRefGoogle Scholar
  119. 119.
    Spivak JL (1988) The anemic patient. In: Harvey AM, Johns RJ, McKusick VA, Owens Jr AH, Ross RS (eds) The principles and practice of medicine, 22 edn. Appleton & Lange, Norwalk, CT, pp 310–314Google Scholar
  120. 120.
    Stenvinkel P (1998) Leptin — a new hormone of definite interest for the nephrologist. Nephrol Dial Transplant 13: 1099–1101PubMedCrossRefGoogle Scholar
  121. 121.
    Stivelman JC (2000) Benefits of anaemia treatment on cognitive function. Nephrol Dial Transplant 15: 29–35PubMedCrossRefGoogle Scholar
  122. 122.
    Stockenhuber F, Kurz RW, Geissler K, Jahn C, Hinterberger W, Balcke P, Lechner K (1990) Recombinant human erythropoietin activates a broad spectrum of progenitor cells. Kidney Int 37: 150–156PubMedCrossRefGoogle Scholar
  123. 123.
    Tielemans CL, Lenclud CM, Wens R, Collart FE, Dratwa M (1989) Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant 4: 883–887PubMedGoogle Scholar
  124. 124.
    Valderrabano F (1996) Erythropoietin in chronic renal failure. Kidney Int 50: 1373–1391PubMedCrossRefGoogle Scholar
  125. 125.
    Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P (1998) Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25 (Suppl 1): 39–47PubMedGoogle Scholar
  126. 126.
    Vanholder R, Van Biesen W, Ringoir S (1993) Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 44: 208–214PubMedCrossRefGoogle Scholar
  127. 127.
    Varat MA, Adolph RJ, Fowler NO (1972) Cardiovascular effects of anemia. Am Heart J 83: 415–426PubMedCrossRefGoogle Scholar
  128. 128.
    Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 (Suppl 2): 4–12PubMedGoogle Scholar
  129. 129.
    Weinberg ED (1999) Iron therapy and cancer. Kidney Int Suppl 69: S131 - S134PubMedCrossRefGoogle Scholar
  130. 130.
    Weiss G, Houston T, Kastner S, Johrer K, Grunewald K, Brock JH (1997) Regulation of cellular iron metabolism by erythropoietin: activation of iron-regulatory protein and upregulation of transferrin receptor expression in erythroid cells. Blood 89: 680–687PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2002

Authors and Affiliations

  1. 1.Department of Internal Medicine (Cancer Research), West German Cancer CenterUniversity of Essen Medical SchoolEssenGermany

Personalised recommendations